JP5738871B2 - β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 - Google Patents
β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 Download PDFInfo
- Publication number
- JP5738871B2 JP5738871B2 JP2012533204A JP2012533204A JP5738871B2 JP 5738871 B2 JP5738871 B2 JP 5738871B2 JP 2012533204 A JP2012533204 A JP 2012533204A JP 2012533204 A JP2012533204 A JP 2012533204A JP 5738871 B2 JP5738871 B2 JP 5738871B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- methyl
- tert
- agonist
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003149 muscarinic antagonist Substances 0.000 title claims description 103
- 238000002648 combination therapy Methods 0.000 title description 22
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 98
- 239000000556 agonist Substances 0.000 claims description 75
- 239000005557 antagonist Substances 0.000 claims description 35
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 32
- 229960005434 oxybutynin Drugs 0.000 claims description 32
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 32
- 229960004045 tolterodine Drugs 0.000 claims description 32
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 32
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical group C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims description 30
- 229960002677 darifenacin Drugs 0.000 claims description 29
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 26
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 25
- 208000020629 overactive bladder Diseases 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- RPMBYDYUVKEZJA-UHFFFAOYSA-N methoctramine Chemical group COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC1=CC=CC=C1OC RPMBYDYUVKEZJA-UHFFFAOYSA-N 0.000 claims description 14
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 claims description 11
- 238000013270 controlled release Methods 0.000 claims description 8
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 claims description 7
- 229960002978 fesoterodine Drugs 0.000 claims description 7
- 229960003510 propiverine Drugs 0.000 claims description 7
- 229960003855 solifenacin Drugs 0.000 claims description 7
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims description 7
- 229960001491 trospium Drugs 0.000 claims description 7
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims description 7
- FJADIVYKWUDMEW-PSXMRANNSA-N 2-[(3s)-1-[7-[[1-[(4-methoxypyridin-3-yl)methyl]piperidin-4-yl]-propan-2-ylamino]heptyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Chemical compound COC1=CC=NC=C1CN1CCC(N(CCCCCCCN2C[C@@H](CC2)C(C(N)=O)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(C)C)CC1 FJADIVYKWUDMEW-PSXMRANNSA-N 0.000 claims description 5
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 claims description 5
- 229950005396 imidafenacin Drugs 0.000 claims description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 183
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 131
- 239000000243 solution Substances 0.000 description 86
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- 238000000034 method Methods 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 150000001875 compounds Chemical class 0.000 description 69
- 235000019439 ethyl acetate Nutrition 0.000 description 68
- 230000008569 process Effects 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- 239000000543 intermediate Substances 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 33
- 230000002195 synergetic effect Effects 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- -1 S-oxybutynin) Chemical compound 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 230000008602 contraction Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- 239000012299 nitrogen atmosphere Substances 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 239000012267 brine Substances 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000011368 organic material Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 11
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 229940125797 compound 12 Drugs 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000008485 antagonism Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003039 volatile agent Substances 0.000 description 9
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 229940126543 compound 14 Drugs 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 230000005714 functional activity Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YWEKHOLXLSSHIN-UHFFFAOYSA-N benzyl n-[3-(2-oxobut-3-enyl)phenyl]carbamate Chemical compound C=CC(=O)CC1=CC=CC(NC(=O)OCC=2C=CC=CC=2)=C1 YWEKHOLXLSSHIN-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical group OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- OVJDMRFKXJASOQ-KPRFIHOGSA-N tert-butyl (5r)-2-[(4-aminophenyl)methyl]-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=2C=CC=CC=2)C1CC1=CC=C(N)C=C1 OVJDMRFKXJASOQ-KPRFIHOGSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ZMNIFUPSXOWURI-UHFFFAOYSA-N 2-(3-methyl-1,2,4-triazol-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C=NC(C)=N1 ZMNIFUPSXOWURI-UHFFFAOYSA-N 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 5
- 102000017910 Adrenergic receptor Human genes 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 5
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 4
- QQAPPTIFMLODJN-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4,5,6,7-tetrahydro-1,3-benzothiazole-4-carboxylic acid Chemical compound OC(=O)C1CCCC2=C1N=C(NC(=O)OC(C)(C)C)S2 QQAPPTIFMLODJN-UHFFFAOYSA-N 0.000 description 4
- VFRODOHJPWZONY-UHFFFAOYSA-N 2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazole-4-carboxylic acid Chemical compound OC(=O)C1CCCC2=C1N=C(C)S2 VFRODOHJPWZONY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- OVJDMRFKXJASOQ-TWJOJJKGSA-N tert-butyl (2r,5r)-2-[(4-aminophenyl)methyl]-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidine-1-carboxylate Chemical compound C([C@@H]1N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C1=CC=C(N)C=C1 OVJDMRFKXJASOQ-TWJOJJKGSA-N 0.000 description 4
- VRXPQQXYKBVWMO-UHFFFAOYSA-N tert-butyl 2-(3-methyl-1,2,4-triazol-1-yl)propanoate Chemical compound CC(C)(C)OC(=O)C(C)N1C=NC(C)=N1 VRXPQQXYKBVWMO-UHFFFAOYSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- NVNDBUIYEOKTDY-ZETCQYMHSA-N (3s)-5-oxo-2,3-dihydro-1h-indolizine-3-carboxylic acid Chemical compound C1=CC(=O)N2[C@H](C(=O)O)CCC2=C1 NVNDBUIYEOKTDY-ZETCQYMHSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- OVJDMRFKXJASOQ-JIMJEQGWSA-N tert-butyl (2s,5r)-2-[(4-aminophenyl)methyl]-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidine-1-carboxylate Chemical compound C([C@H]1N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C1=CC=C(N)C=C1 OVJDMRFKXJASOQ-JIMJEQGWSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- PBFRLNSQQDIADY-IAGOWNOFSA-N (2r)-2-[(s)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]hex-5-ynoic acid Chemical compound C#CCC[C@@H](C(O)=O)[C@H](O[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 PBFRLNSQQDIADY-IAGOWNOFSA-N 0.000 description 2
- WIVBNGYRUYSJKJ-VIFPVBQESA-N (2s)-1-(1,3-benzothiazol-2-yl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C1=NC2=CC=CC=C2S1 WIVBNGYRUYSJKJ-VIFPVBQESA-N 0.000 description 2
- OZXUSBILVIKYQB-YZWUSWEISA-N (3r)-n-[4-[[(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-5-oxo-2,3-dihydro-1h-indolizine-3-carboxamide Chemical compound C1([C@H]([C@@H]2N[C@H](CC=3C=CC(NC(=O)[C@@H]4N5C(=O)C=CC=C5CC4)=CC=3)CC2)O)=CC=CC=C1 OZXUSBILVIKYQB-YZWUSWEISA-N 0.000 description 2
- OZXUSBILVIKYQB-GEMTWJNPSA-N (3s)-n-[4-[[(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-5-oxo-2,3-dihydro-1h-indolizine-3-carboxamide Chemical compound C1([C@H]([C@@H]2N[C@H](CC=3C=CC(NC(=O)[C@H]4N5C(=O)C=CC=C5CC4)=CC=3)CC2)O)=CC=CC=C1 OZXUSBILVIKYQB-GEMTWJNPSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 2
- GDTSQDORVLBGMT-UHFFFAOYSA-N 1-(3-chlorophenyl)prop-2-en-1-ol Chemical compound C=CC(O)C1=CC=CC(Cl)=C1 GDTSQDORVLBGMT-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- JBQMFBWTKWOSQX-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCC2=C1 JBQMFBWTKWOSQX-UHFFFAOYSA-N 0.000 description 2
- DYCLHZPOADTVKK-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-4-yl)acetate Chemical compound NC1=NC(CC(O)=O)=CS1 DYCLHZPOADTVKK-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- VYPHJAUWQKZZHU-UHFFFAOYSA-N 2-[3-(phenylmethoxycarbonylamino)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(NC(=O)OCC=2C=CC=CC=2)=C1 VYPHJAUWQKZZHU-UHFFFAOYSA-N 0.000 description 2
- LBCVPYBBUCWRLU-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxy-2-(3-chlorophenyl)acetaldehyde Chemical compound CC(C)(C)[Si](C)(C)OC(C=O)C1=CC=CC(Cl)=C1 LBCVPYBBUCWRLU-UHFFFAOYSA-N 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- UGHITQRMICHJDI-UHFFFAOYSA-N 4-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]benzenesulfonyl chloride Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CSC(C=2C=CC(=CC=2)S(Cl)(=O)=O)=N1 UGHITQRMICHJDI-UHFFFAOYSA-N 0.000 description 2
- PVQXQGFENHRWDS-XMCWYHTOSA-N 4-[[(5r)-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-(3-chlorophenyl)methyl]pyrrolidin-2-yl]methyl]aniline Chemical compound C([C@@H](N1)[C@H](O[Si](C)(C)C(C)(C)C)C=2C=C(Cl)C=CC=2)CC1CC1=CC=C(N)C=C1 PVQXQGFENHRWDS-XMCWYHTOSA-N 0.000 description 2
- FCKGESYAHWACQR-XMCWYHTOSA-N 4-[[(5r)-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidin-2-yl]methyl]aniline Chemical compound C([C@@H](N1)[C@H](O[Si](C)(C)C(C)(C)C)C=2C=CC=CC=2)CC1CC1=CC=C(N)C=C1 FCKGESYAHWACQR-XMCWYHTOSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CGHKAHXRRZYEFD-IAGOWNOFSA-N CCCCOC(N([C@@H]1CCC=O)C(C)(C)O[C@@H]1C1=CC=CC=C1)=O Chemical compound CCCCOC(N([C@@H]1CCC=O)C(C)(C)O[C@@H]1C1=CC=CC=C1)=O CGHKAHXRRZYEFD-IAGOWNOFSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- IFGMRYWYMYRAPQ-UHFFFAOYSA-N ethyl 2-[3-(phenylmethoxycarbonylamino)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(NC(=O)OCC=2C=CC=CC=2)=C1 IFGMRYWYMYRAPQ-UHFFFAOYSA-N 0.000 description 2
- NNEBHSVVRNIDMV-UHFFFAOYSA-N ethyl 2-amino-4,5,6,7-tetrahydro-1,3-benzothiazole-4-carboxylate Chemical compound CCOC(=O)C1CCCC2=C1N=C(N)S2 NNEBHSVVRNIDMV-UHFFFAOYSA-N 0.000 description 2
- TVULSXCAFGMKQR-UHFFFAOYSA-N ethyl 2-methyl-4,5,6,7-tetrahydro-1,3-benzothiazole-4-carboxylate Chemical compound CCOC(=O)C1CCCC2=C1N=C(C)S2 TVULSXCAFGMKQR-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000036724 intravesical pressure Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- ZGDXLVVSZMKXPU-QMMMGPOBSA-N methyl (3s)-5-oxo-2,3-dihydro-1h-indolizine-3-carboxylate Chemical compound C1=CC(=O)N2[C@H](C(=O)OC)CCC2=C1 ZGDXLVVSZMKXPU-QMMMGPOBSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000036453 micturition reflex Effects 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- RWTDQXJJJLIHDK-UHFFFAOYSA-N n-[1-[tert-butyl(dimethyl)silyl]oxy-1-(3-chlorophenyl)but-3-en-2-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(=O)NC(C=C)C(O[Si](C)(C)C(C)(C)C)C1=CC=CC(Cl)=C1 RWTDQXJJJLIHDK-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- BTXYRUJPXJOEHP-NJDAHSKKSA-N tert-butyl (2r,5r)-2-[(4-aminophenyl)methyl]-5-[(r)-hydroxy(phenyl)methyl]pyrrolidine-1-carboxylate Chemical compound C([C@@H]1N([C@H](CC1)[C@H](O)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C1=CC=C(N)C=C1 BTXYRUJPXJOEHP-NJDAHSKKSA-N 0.000 description 2
- BTXYRUJPXJOEHP-PWRODBHTSA-N tert-butyl (2s,5r)-2-[(4-aminophenyl)methyl]-5-[(r)-hydroxy(phenyl)methyl]pyrrolidine-1-carboxylate Chemical compound C([C@H]1N([C@H](CC1)[C@H](O)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C1=CC=C(N)C=C1 BTXYRUJPXJOEHP-PWRODBHTSA-N 0.000 description 2
- XKXIQBVKMABYQJ-UHFFFAOYSA-M tert-butyl carbonate Chemical compound CC(C)(C)OC([O-])=O XKXIQBVKMABYQJ-UHFFFAOYSA-M 0.000 description 2
- GNUXVCXXWDAPTL-UHFFFAOYSA-N tert-butyl-[1-(3-chlorophenyl)prop-2-enoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC(C=C)C1=CC=CC(Cl)=C1 GNUXVCXXWDAPTL-UHFFFAOYSA-N 0.000 description 2
- GGZWMMZEAPJGFL-YMPZKCBVSA-N tert-butyl-dimethyl-[(r)-[(2r,5r)-5-[(4-nitrophenyl)methyl]pyrrolidin-2-yl]-phenylmethoxy]silane Chemical compound C([C@H]1CC[C@@H](N1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C1=CC=C([N+]([O-])=O)C=C1 GGZWMMZEAPJGFL-YMPZKCBVSA-N 0.000 description 2
- GGZWMMZEAPJGFL-MDNUFGMLSA-N tert-butyl-dimethyl-[(r)-[(2r,5s)-5-[(4-nitrophenyl)methyl]pyrrolidin-2-yl]-phenylmethoxy]silane Chemical compound C([C@@H]1CC[C@@H](N1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C1=CC=C([N+]([O-])=O)C=C1 GGZWMMZEAPJGFL-MDNUFGMLSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- KEPNNKBVVAECRB-VXGBXAGGSA-N (2r)-2-[(s)-hydroxy(phenyl)methyl]hex-5-ynoic acid Chemical compound C#CCC[C@@H](C(O)=O)[C@H](O)C1=CC=CC=C1 KEPNNKBVVAECRB-VXGBXAGGSA-N 0.000 description 1
- IPJPTPFIJLFWLP-UHFFFAOYSA-M (4-nitrophenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].C1=CC([N+](=O)[O-])=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 IPJPTPFIJLFWLP-UHFFFAOYSA-M 0.000 description 1
- QDMNNMIOWVJVLY-MRVPVSSYSA-N (4s)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1C1=CC=CC=C1 QDMNNMIOWVJVLY-MRVPVSSYSA-N 0.000 description 1
- CYXDECLVKQCMGJ-DEDYPNTBSA-N (ne)-n-[2-[tert-butyl(dimethyl)silyl]oxy-2-(3-chlorophenyl)ethylidene]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(=O)\N=C\C(O[Si](C)(C)C(C)(C)C)C1=CC=CC(Cl)=C1 CYXDECLVKQCMGJ-DEDYPNTBSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- XLHUBROMZOAQMV-UHFFFAOYSA-N 1,4-benzosemiquinone Chemical group [O]C1=CC=C(O)C=C1 XLHUBROMZOAQMV-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- SCCCFNJTCDSLCY-UHFFFAOYSA-N 1-iodo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(I)C=C1 SCCCFNJTCDSLCY-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- CQCAYWAIRTVXIY-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetaldehyde Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC=O)C1=CC=CC=C1 CQCAYWAIRTVXIY-UHFFFAOYSA-N 0.000 description 1
- OOGJQPCLVADCPB-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-FQEVSTJZSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DRLMMVPCYXFPEP-UHFFFAOYSA-N 2-bromo-1,3-benzothiazole Chemical compound C1=CC=C2SC(Br)=NC2=C1 DRLMMVPCYXFPEP-UHFFFAOYSA-N 0.000 description 1
- SKFNPANWNXDUHL-UHFFFAOYSA-N 2-hex-3-enylnon-7-enoic acid Chemical compound CCC=CCCC(CCCCC=CC)C(=O)O SKFNPANWNXDUHL-UHFFFAOYSA-N 0.000 description 1
- PULPQOUKKDDVFR-UHFFFAOYSA-N 2-nitroethynylbenzene Chemical group [O-][N+](=O)C#CC1=CC=CC=C1 PULPQOUKKDDVFR-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- NCTCGHLIHJJIBK-UHFFFAOYSA-N 3-phenyl-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1=CC=CC=C1 NCTCGHLIHJJIBK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VQFOHZWOKJQOGO-UHFFFAOYSA-N 4-fluorobenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(F)C=C1 VQFOHZWOKJQOGO-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N 5-methyl-1h-1,2,4-triazole Chemical compound CC1=NC=NN1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- UIMCBBHQYJHFDA-IEWAYXNBSA-N C(C)(C)(C)N1C(O[C@@H]([C@H]1\C=C\C=O)C1=CC=CC=C1)(C)C Chemical compound C(C)(C)(C)N1C(O[C@@H]([C@H]1\C=C\C=O)C1=CC=CC=C1)(C)C UIMCBBHQYJHFDA-IEWAYXNBSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000780539 Homo sapiens Beta-3 adrenergic receptor Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 229940126083 M3 antagonist Drugs 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- YJBKAMMKXVRSAI-CUCKRJOPSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] n-(3-fluorophenyl)-n-[(3,4,5-trifluorophenyl)methyl]carbamate;(2s,3s)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.FC1=CC=CC(N(CC=2C=C(F)C(F)=C(F)C=2)C(=O)O[C@@H]2C3CCN(CC3)C2)=C1 YJBKAMMKXVRSAI-CUCKRJOPSA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- PQQYGSFFNZLVCT-UHFFFAOYSA-N benzyl n-[3-[2-[methoxy(methyl)amino]-2-oxoethyl]phenyl]carbamate Chemical compound CON(C)C(=O)CC1=CC=CC(NC(=O)OCC=2C=CC=CC=2)=C1 PQQYGSFFNZLVCT-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- YOMWYEITAAOYEC-UHFFFAOYSA-N butane-2-sulfinamide Chemical compound CCC(C)S(N)=O YOMWYEITAAOYEC-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- CFUIEWJMKUMJJA-UHFFFAOYSA-L copper dichloromethane sulfate Chemical compound S(=O)(=O)([O-])[O-].[Cu+2].C(Cl)Cl CFUIEWJMKUMJJA-UHFFFAOYSA-L 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FGSGHBPKHFDJOP-UHFFFAOYSA-N ethyl 2-oxocyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCCCC1=O FGSGHBPKHFDJOP-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- VPFMEXRVUOPYRG-UHFFFAOYSA-N hex-5-ynoic acid Chemical compound OC(=O)CCCC#C VPFMEXRVUOPYRG-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- WGSPBWSPJOBKNT-UHFFFAOYSA-N iodocyanopindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C(I)=C(C#N)N2 WGSPBWSPJOBKNT-UHFFFAOYSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LZBWETNXIZOALQ-YFKPBYRVSA-N methyl (2s)-5-methoxy-3,4-dihydro-2h-pyrrole-2-carboxylate Chemical compound COC(=O)[C@@H]1CCC(OC)=N1 LZBWETNXIZOALQ-YFKPBYRVSA-N 0.000 description 1
- BVKGNQRDVFGNIW-UHFFFAOYSA-N methyl 2-(3-aminophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(N)=C1 BVKGNQRDVFGNIW-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZNTDIRUBXSTBGJ-NRFANRHFSA-N n-[4-[2-[[(2s)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide Chemical compound C([C@H](O)COC=1C=CC(O)=CC=1)NCCC(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(I)C=C1 ZNTDIRUBXSTBGJ-NRFANRHFSA-N 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- BCQGLRUZHQRSDG-UHFFFAOYSA-N non-7-en-4-one Chemical compound CCCC(=O)CCC=CC BCQGLRUZHQRSDG-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- XWRDGWGYYMWOFB-UHFFFAOYSA-N propane-1-sulfinamide Chemical compound CCCS(N)=O XWRDGWGYYMWOFB-UHFFFAOYSA-N 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940052907 telazol Drugs 0.000 description 1
- 229950000334 temiverine Drugs 0.000 description 1
- JEZAEXKOVWLWMS-JIMJEQGWSA-N tert-butyl (2r,5s)-2-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]-5-[(4-nitrophenyl)methyl]pyrrolidine-1-carboxylate Chemical compound C([C@H]1N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C1=CC=C([N+]([O-])=O)C=C1 JEZAEXKOVWLWMS-JIMJEQGWSA-N 0.000 description 1
- JMGHGEYXOAMGAW-PKZQBKLLSA-N tert-butyl (2s,5r)-2-[[4-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]phenyl]methyl]-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-phenylmethyl]pyrrolidine-1-carboxylate Chemical compound C([C@H]1N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C(=O)OC(C)(C)C)C(C=C1)=CC=C1NC(=O)CC1=CSC(N)=N1 JMGHGEYXOAMGAW-PKZQBKLLSA-N 0.000 description 1
- RGRHTWRHFMPMPJ-IEWAYXNBSA-N tert-butyl (4r,5r)-2,2-dimethyl-4-[(e)-3-oxoprop-1-enyl]-5-phenyl-1,3-oxazolidine-3-carboxylate Chemical compound O1C(C)(C)N(C(=O)OC(C)(C)C)[C@H](\C=C\C=O)[C@H]1C1=CC=CC=C1 RGRHTWRHFMPMPJ-IEWAYXNBSA-N 0.000 description 1
- WXNRHYJQUFTWMA-GRSLCELMSA-N tert-butyl (4r,5r)-2,2-dimethyl-4-[(e)-4-(4-nitrophenyl)but-3-enyl]-5-phenyl-1,3-oxazolidine-3-carboxylate Chemical compound C([C@H]1N(C(O[C@@H]1C=1C=CC=CC=1)(C)C)C(=O)OC(C)(C)C)C\C=C\C1=CC=C([N+]([O-])=O)C=C1 WXNRHYJQUFTWMA-GRSLCELMSA-N 0.000 description 1
- WXNRHYJQUFTWMA-RDBXNYSNSA-N tert-butyl (4r,5r)-2,2-dimethyl-4-[(z)-4-(4-nitrophenyl)but-3-enyl]-5-phenyl-1,3-oxazolidine-3-carboxylate Chemical compound C([C@H]1N(C(O[C@@H]1C=1C=CC=CC=1)(C)C)C(=O)OC(C)(C)C)C\C=C/C1=CC=C([N+]([O-])=O)C=C1 WXNRHYJQUFTWMA-RDBXNYSNSA-N 0.000 description 1
- CFDANAWGFQCDPJ-ZIAGYGMSSA-N tert-butyl (4s,5r)-4-formyl-2,2-dimethyl-5-phenyl-1,3-oxazolidine-3-carboxylate Chemical compound O1C(C)(C)N(C(=O)OC(C)(C)C)[C@H](C=O)[C@H]1C1=CC=CC=C1 CFDANAWGFQCDPJ-ZIAGYGMSSA-N 0.000 description 1
- KTGLHJQYWYSTHR-KPRFIHOGSA-N tert-butyl (5r)-2-[(4-aminophenyl)methyl]-5-[(r)-[tert-butyl(dimethyl)silyl]oxy-(3-chlorophenyl)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N([C@H](CC1)[C@H](O[Si](C)(C)C(C)(C)C)C=2C=C(Cl)C=CC=2)C1CC1=CC=C(N)C=C1 KTGLHJQYWYSTHR-KPRFIHOGSA-N 0.000 description 1
- FQHZCHGMQDPTNC-KYYKXEFOSA-N tert-butyl-dimethyl-[(r)-[(2r,5r)-5-[nitro(phenyl)methyl]pyrrolidin-2-yl]-phenylmethoxy]silane Chemical compound [O-][N+](=O)C([C@H]1CC[C@@H](N1)[C@H](O[Si](C)(C)C(C)(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 FQHZCHGMQDPTNC-KYYKXEFOSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Description
驚くべきことに、β3アドレナリン作動性受容体アゴニスト(以降、「β3−ARアゴニスト」)、抗ムスカリン剤、及び任意の選択的M2アンタゴニストを用いた併用療法が、過活動膀胱の治療に相乗効果をもたらすことが判明してきた。β3−ARアゴニスト、抗ムスカリン剤、及び任意の選択的M2アンタゴニストを含んでなる組合せ組成物もまた記載される。
本明細書に記載されるのは、過活動膀胱の治療法であり、これにおいて該方法は、β3−ARアゴニスト、抗ムスカリン剤、及び任意の選択的M2アンタゴニストを、それを必要とする患者に投与することを含んでなる。かかる併用療法は、相乗効果及びしたがって、効力の改善及び/又は副作用の低減を提供する。
ベンジル[3−(2−オキソブタ−3−エン−1−イル)フェニル]カルバメート(i−1):
LC−MS:m/z(ES)314(MH)+,336(MNa)+.
LC−MS:m/z(ES)286(MH)+,308(MNa)+.
ル}フェニル)カルバメート
LC−MS:m/z(ES)329(MH)+.
氷/水浴により0℃に冷却された、無水THF 1000mL中のベンジル(3−{2−[メトキシ(メチル)アミノ]−2−オキソエチル}フェニル)カルバメート(工程Cより)15g(45.7mmol)の溶液に、窒素雰囲気下で、ビニルマグネシウムブロミドの1.0M溶液(THF中100mL、100mmol)をカニューレにより滴下添加し、得られた溶液を0℃で1時間攪拌した。5℃未満の温度を保ちながら1M HCl 500mLを徐々に添加することにより、反応物をクエンチし、30分間攪拌した。次に混合物を酢酸エチルで抽出し、合わせた有機物質を水で、続いて食塩水で洗浄した。次いで有機物質を、硫酸ナトリウム上で乾燥し、濾過し、真空下で濃縮した。残渣をバイオタージ(Biotage)75Mフラッシュにより、30%酢酸エチル(ヘキサン中)で溶出して精製し、標題化合物(11g、78%)を明黄色の固体として得た。
LC−MS:m/z(ES)310(MH)+,332(MNa)+.1H NMR(500MHz,CDCl3)δ:7.44−7.36(m,7H),7.18(d,J=8.4Hz,2H),6.70(br s,1H),6.44(dd,J=10.5,17.6Hz,1H),6.32(dd,J=1.1,17.6Hz,1H),5.85(dd,J=1.1,10.5Hz,1H),5.22(s,2H),3.86(s,2H).
((1R)−1−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(3−クロロフェニル)メチル]プロパ−2−エン−1−イル)カルバメート
(i−2)
m/z(ES)168,170(M,M+2)+,190,192(MNa,MNa+2)+.1H NMR(500MHz,CDCl3)δ:7.38(s,1H),7.35−7.22(m,3H),5.90(ddd,J=7.3,10.0,17.4Hz,1H),5.38(d,J=17.5Hz,1H),5.18(d,J=7.2Hz,1H),5.15(d,J=10.1Hz,1H),0.96(s,9H),0.18(s,3H),0.08(s,3H).
m/z(ES)282,284(M,M+2)+;151,153(M−OTBS,M−OTBS+2)+.
m/z(ES)387,390(M,M+2)+.
異性体2:m/z(ES)416,418(M,M+2)+,438,440(MNa,MNa+2)+.1H NMR(500MHz,CDCl3)δ:7.33−7.31(m,2H),7.26(br d,J=5.0Hz,2H),7.20−7.16(m,1H),5.44(ddd,J=7.2,10.0,17.4Hz,1H),5.26(オーバーラップd,J=7.3Hz,1H),5.25(オーバーラップd,J=17.3Hz,1H),4.84(d,J=4.4Hz,1H),4.02(dt,J=4.4,7.8Hz,1H),3.80(d,J=4.4Hz,1H),1.20(s,9H),0.94(s,9H),0.14(s,3H),−0.12(s,3H).
異性体3:m/z(ES)416,418(M,M+2)+,438,440(MNa,MNa+2)+.1H NMR(500MHz,CDCl3)δ:7.32−7.29(m,2H),7.26−7.24(m,2H),7.22−7.20(m,1H),6.04(ddd,J=7.1,10.4,17.4Hz,1H),5.40(d,J=10.2Hz,1H),5.32(d,J=17.3Hz,1H),4.80(d,J=4.0Hz,1H),3.88−3.80(m,1H),3.55(d,J=9.4Hz,1H),1.09(s,9H),0.95(s,9H),0.09(s,3H),−0.10(s,3H).
異性体4:m/z(ES)416,418(M,M+2)+,438,440(MNa,MNa+2)+.1H NMR(500MHz,CDCl3)δ:7.32(s,1H),7.30(br d,J=7.5,1H),7.27−7.25(m,2H),7.21−7.18(m,1H),5.92(ddd,J=7.1,10.3,17.4Hz,1H),5.23(d,J=10.4Hz,1H),5.18(d,J=17.4Hz,1H),4.75(d,J=4.2Hz,1H),3.88−3.82(m,1H),3.33(d,J=9.4Hz,1H),1.19(s,9H),0.94(s,9H),0.09(s,3H),−0.14(s,3H).
N−{1−[{[tert−ブチル(ジメチル)シリル]オキシ}(3−クロロフェニル)メチル]−プロパ−2−エン−1−イル}2−メチルプロパン−2−スルフィンアミドの異性体1(工程Eより)(510mg、2.22mmol)に、ジオキサン中の無水4M HCl 5mLを添加し、溶液を室温で15分間攪拌した。反応物を濃縮乾燥し、トルエン(2x5mL)と共沸させて、過剰のHClを除去した。次いで残渣を、窒素雰囲気下に置かれ、氷/水浴で0℃に冷却された、無水ジクロロメタン中に溶解し、次にベンジルクロロホルマート(0.32mL、2.22mmol)をシリンジにより、続いてジイソプロピルエチルアミン(1.19mL、6.66mmol)を添加し、得られた溶液を0℃で2時間攪拌した。溶液を真空下で濃縮乾燥し、残渣を分取用プレート(4x1000μM)により、20%酢酸エチル(ヘキサン中)で溶出して精製し、標題化合物(703mg、71%)を得た。
m/z(ES)446,448(M,M+2)+,468,470(MNa,MNa+2)+.1H NMR(500MHz,CDCl3)δ:7.32(s,1H),7.30(br d,J=7.5,1H),7.27−7.25(m,2H),7.21−7.18(m,1H),5.92(ddd,J=7.1,10.3,17.4Hz,1H),5.23(d,J=10.4Hz,1H),5.18(d,J=17.4Hz,1H),4.75(d,J=4.2Hz,1H),3.88−3.82(m,1H),3.33(d,J=9.4Hz,1H),1.19(s,9H),0.94(s,9H),0.09(s,3H),−0.14(s,3H).
Tert−ブチル(5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−3)
(i−2)(500mg、1.12mmol)の溶液に、チャン(Zhan)I触媒(740mg、1.12mmol)を添加し、得られた緑色の溶液を、窒素雰囲気下、40℃で一晩加熱した。反応物を濃縮乾燥し、残渣を分取用プレート(4x1000μM)により、40%酢酸エチル(ヘキサン中)で溶出して精製し、標題化合物(348mg、50%)を得た。
m/z(ES)713,715(M,M+2)+,735,737(MNa,MNa+2)+.
m/z(ES)397(MH)+.
5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−3)
無水THF 5mL中の4−({(5R)−5−[(R)−([tert−ブチル(ジメチル)シリル]オキシ)(フェニル)メチル]ピロリジン−2−イル}メチル)アニリン(工程Bより)121mg(0.315mmol)の溶液に、tert−ブチルカルボナート(69mg、0.315mmol)を、続いてTEA(44μL、0.315mmol)を添加し、得られた溶液を、窒素雰囲気下、室温で一晩攪拌した。反応混合物を直接、分取用プレート(1500μM)にのせ、30%酢酸エチル(ヘキサン中)で溶出して、標題化合物(100mg、64%)を得た。
m/z(ES)497(MH)+,397(M−Boc)+.1H NMR(500MHz,CDCl3)δ:7.40−7.30(m,5H),6.75−6.68(m,2H),6.56−6.51(m,2H),5.52−5.48(m,1H),5.32−5.28(m,1H),4.16−4.06(m,2H),3.88−3.82(m,1H),3.76−3.70(m,1H),3.55−3.48(m,2H),2.74(br d,J=11.8Hz,1H),2.44(br d,J=11.8Hz,1H),2.05−1.94(m,1H),1.90−1.82(m,1H),1.60(s,9H),1.50−1.42(m,1H),1.32−1.22(m,2H),1.10−1.02(m,1H),0.95(s,9H),0.08(s,3H),−0.15(s,3H).
Tert−ブチル(2S,5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−4a);
Tert−ブチル(2R,5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−4b)
中間体i−3(tert−ブチル(5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(シス及びトランスの4:1混合物)を、メタノール中に溶解し、バージャー(Berger)マルチグラム(Multigram)SFC(超臨界)により、30%メタノール:60%二酸化炭素の溶出液を用いて精製し、2つのジアステレオマーを分離した。カラムの最初の異性体を、副異性体1とし、2番目の異性体を主異性体2と標識した。
i−4a:m/z(ES)497(MH)+,397(M−Boc)+.1H NMR(500MHz,CDCl3)δ:7.40−7.30(m,5H),6.75−6.68(m,2H),6.56−6.51(m,2H),5.52−5.48(m,1H),5.32−5.28(m,1H),4.16−4.06(m,2H),3.88−3.82(m,1H),3.76−3.70(m,1H),3.55−3.48(m,2H),2.74(br d,J=11.8Hz,1H),2.44(br d,J=11.8Hz,1H),2.05−1.94(m,1H),1.90−1.82(m,1H),1.60(s,9H),1.50−1.42(m,1H),1.32−1.22(m,2H),1.10−1.02(m,1H),0.95(s,9H),0.92(d,J=11.8Hz,1H),0.12(br d,J=14.0Hz,3H),−0.04(s,3H).SFCで8.70minに溶出、異性体2。
i−4b:m/z(ES)497(MH)+,397(M−Boc)+.1H NMR(500MHz,CDCl3)δ:7.40−7.30(m,5H),6.76−6.68(m,2H),6.56−6.51(m,2H),5.52−5.48(m,1H),5.32−5.28(m,1H),4.16−4.06(m,2H),3.88−3.82(m,1H),3.76−3.70(m,1H),3.60−3.46(m,2H),2.72(br d,J=12.0Hz,1H),2.44(br d,J=12.2Hz,1H),2.05−1.94(m,1H),1.90−1.82(m,1H),1.64(s,9H),1.50−1.42(m,1H),1.32−1.22(m,2H),1.10−1.02(m,1H),0.95(s,9H),0.14(br d,J=13.8Hz,3H),0.09(s,3H).SFCで7.78minに溶出、異性体1。
Tert−ブチル(2S,5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−4a);
Tert−ブチル(2R,5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(フェニル)メチル]ピロリジン−1−カルボキシラート(i−4b)
1H NMR(500MHz,CDCl3):δ7.40−7.37(m,2H),7.36−7.32(m,1H),7.31−7.28(m,2H),5.42(dd,J=8.9,3.7Hz,1H),4.69(t,J=8.9Hz,1H),4.28(dd,J=9.2,3.7Hz,1H),3.13−3.02(m,2H),2.24−2.21(m,2H),1.94(t,J=2.6Hz,1H),1.84(quintet,J=7.1Hz,2H).
LC−MS:m/z(ES)258.2(MH)+.
1H NMR(500MHz,CDCl3):δ7.30−7.28(m,8H),7.09−7.07(m,2H),5.42(dd,J=8.7,3.7Hz,1H),4.76−4.72(m,1H),4.72−4.67(m,1H),4.65(t,J=8.7Hz,1H),4.18(dd,J=8.7,3.7Hz,1H),3.05(d,J=7.8Hz,1H),2.24(td,J=7.1,2.5Hz,2H),2.00−1.93(m,2H),1.67−1.61(m,1H).
LC−MS:m/z(ES)346.1(MH−H2O)+,386.0(MNa)+.
1H NMR(500MHz,CDCl3):δ7.39−7.28(m,5H),4.85(d,J=8.2,1H),3.03−2.97(m,1H),2.29−2.15(m,2H),1.97(t,J=2.5Hz,1H),1.93−1.82(m,1H),1.62−1.55(m,1H).
LC−MS:m/z(ES)201.0(MH−H2O)+.
1H NMR(500MHz,CDCl3):δ7.36−7.27(m,5H),4.78(d,J=8.7,1H),2.90−2.86(m,1H),2.19−2.11(m,1H),2.10−2.03(m,1H),1.90(t,J=2.6Hz,1H),1.75−1.67(m,1H),1.41−1.34(m,1H),0.83(s,9H),0.02(s,3H),−0.27(s,3H).
LC−MS:m/z(ES)333.2(MH)+.
1H NMR(500MHz,CDCl3):7.28−7.21(m,7H),6.87(d,J=8.4Hz,2H),4.92(s,2H),4.77−4.59(m,2H),3.89−3.84(m,1H),3.81(s,3H),2.30−2.22(m,2H),1.95(m,1H),1.91−1.85(m,1H),1.57−1.50(m,1H),0.89(s,9H),0.06(s,3H),−0.15(s,3H).
LC−MS:m/z(ES)468.1(MH)+,490.0(MNa)+.
1H NMR(500MHz,CDCl3):8.11−8.04(m,2H),7.94−8.01(m,1H),7.38−7.21(m,8H),6.87(d,J=8.4Hz,2H),4.98(s,2H),4.77−4.59(m,2H),4.00−3.95(m,3H),3.81(s,3H),2.56(t,J=7.1Hz,H=2H),2.00−1.95(m,1H),1.66−1.61(m,1H),0.93(s,9H),0.10(s,3H),−0.10(s,3H).
LC−MS:m/z(ES)589.3(MH)+,611.2(MNa)+.
1H NMR(500MHz,CDCl3):8.17−8.14(m,2H),7.32−7.23(m,9H),6.87(d,J=8.4Hz,2H),4.96(d,J=12.2Hz,1H),4.90(d,J=12.1Hz,1H),4.72(d,J=3Hz,1H),4.16−4.13(m,1H),3.81(s,3H),3.71−3.77(m,2H),2.65−2.52(m,2H),1.97−1.92(m,1H),1.72−1.60(m,1H),0.93(s,9H),0.05(s,3H),−0.13(s,3H).
異性体1:LC−MS:m/z(ES)427.3(MH)+
異性体2:LC−MS:m/z(ES)427.3(MH)+
LC−MS:m/z(ES)527.3(MH)+,549.2(MNa)+.
LC−MS:m/z(ES)527.3(MH)+,549.2(MNa)+.
m/z(ES)497(MH)+,397(M−Boc)+.1H NMR(500MHz,CDCl3)δ:7.38−7.29(m,5H),6.76−6.68(m,2H),6.55−6.50(m,2H),5.52−5.49(m,1H),5.30−5.27(m,1H),4.15−4.05(m,2H),3.86−3.81(m,1H),3.76−3.71(m,1H),3.55−3.47(m,2H),2.74(br d,J=11.7Hz,1H),2.44(br d,J=11.7Hz,1H),2.05−1.93(m,1H),1.90−1.83(m,1H),1.60(s,9H),1.50−1.42(m,1H),1.31−1.21(m,2H),1.10−1.02(m,1H),0.95(s,9H),0.92(d,J=11.8Hz,1H),0.13(br d,J=14.0Hz,3H),−0.05(s,3H)
m/z(ES)497(MH)+,397(M−Boc)+.1H NMR(500MHz,CDCl3)δ:7.41−7.30(m,5H),6.73−6.67(m,2H),6.56−6.50(m,2H),5.52−5.48(m,1H),5.33−5.28(m,1H),4.15−4.06(m,2H),3.86−3.81(m,1H),3.76−3.70(m,1H),3.59−3.46(m,2H),2.72(br d,J=12.0Hz,1H),2.44(br d,J=12.0Hz,1H),2.05−1.93(m,1H),1.90−1.82(m,1H),1.64(s,9H),1.49−1.42(m,1H),1.32−1.20(m,2H),1.10−1.02(m,1H),0.95(s,9H),0.14(br d,J=13.7Hz,3H),0.10(s,3H).
Tert−ブチル(5R)−2−(4−アミノベンジル)−5−[(R)−{[tert−ブチル(ジメチル)シリル]オキシ}(3−クロロフェニル)メチル]ピロリジン−1−カルボキシラート(i−5)
m/z(ES)430,432(M,M+2)+.
無水THF 1mL中の4−({(5R)−5−[(R)−([tert−ブチル(ジメチル)シリル]オキシ)(3−クロロフェニル)メチル]ピロリジン−2−イル}メチル)アニリン(工程Aより)33mg(0.07mmol)の溶液に、tert−ブチルカルボナート(15.3mg、0.07mmol)を、続いてTEA(13uL、0.07mmol)を添加し、得られた溶液を、窒素雰囲気下、室温で一晩攪拌した。反応混合物を直接、分取用プレート(500uM)にのせ、30%酢酸エチル(ヘキサン中)で溶出して、標題化合物(25mg、78%)を得た。
m/z(ES)530,532(M,M+2)+,430,432(M−Boc,M−Boc+2)+.
4−{4−[4−(トリフルオロメチル)フェニル]−1,3−チアゾール−2−イル}ベンゼンスルホニルクロリド(i−6)
2−メチル−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボン酸(i−7)
1H NMR(500MHz,CDCl3)δ:4.22(q,J=7.0Hz,2H),3.96(m,1H),3.04(m,1H),2.88(m,1H),2.76(m,2H),2.70(s,3H),1.30(t,J=7.0Hz,3H).
THF(450mL)及びメタノール(100mL)中のエチル2−メチル−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボキシラート(工程Aより)31.5g(149mmol)の溶液に、水酸化リチウム(1M溶液を149mL、149mmol)を添加し、得られた混合物を室温で3時間攪拌した。有機物質を蒸発により除去し、水性残渣をEt2O(2x250mL)で抽出し、1M 塩酸(約170mL)の添加によりpH3に酸性化し、固体NaClで飽和させた。DCM(3x250mL)で抽出し、合わせたDCM層をMgSO4上で乾燥し、濾過し、蒸発させた。残渣をアセトニトリルで粉砕し、濾過し、乾燥させて、標題化合物(7.1g、26%)を灰白色の固体として得た。
1H NMR(500MHz,CDCl3)δ:11.75(br s,1H),4.02(m,1H),3.00(m,1H),2.90−2.66(m,6H).
2−[(Tert−ブトキシカルボニル)アミノ]−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボン酸(i−8)
1H NMR(500MHz,CDCl3)δ:5.30(br s,2H),4.21(q,J=7.0,2H),3.81(m,1H),2.91(m,1H),2.78(m,1H),2.66(m,2H),1.30(t,J=7.0,3H).
1H NMR(500MHz,CDCl3)δ:9.23(br s,1H),4.17(q,J=7.1Hz,2H),3.95(t,J=6.6Hz,1H),3.04(m,1H),2.86(m,1H),2.76(m,2H),1.55(s,9H),1.23(t,J=7.1Hz,3H).
エチル2−[(tert−ブトキシカルボニル)アミノ]−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボキシラート(工程Bより)から、中間体(i−7)工程Bに見られるものと類似の方法を用いて調製した。
1H NMR(500MHz,CDCl3)δ:3.96(m,1H),3.06(m,1H),2.88(m,2H),2.71(m,1H),1.55(s,9H).
2−(4−フルオロフェニル)−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボン酸(i−9)
1H NMR(500MHz,DMSO−d6)δ:7.90(m,2H),7.29(t,J=8.7,2H),3.81(m,1H),2.99(m,1H),2.86(m,1H),2.70−2.58(m,2H).
2−メチル−4,5,6,7−テトラヒドロ−1,3−ベンゾチアゾール−4−カルボン酸(i−10)
1H NMR(500MHz,CDCl3)δ:4.22(q,J=7.1,2H),3.84(t,J=5.5,1H),2.80(m,1H),2.73(m,1H),2.65(s,3H),2.18(m,1H),2.11−1.95(m,2H),1.85(m,1H),1.29(t,J=7.1,3H).
エチル2−メチル−4,5,6,7−テトラヒドロ−1,3−ベンゾチアゾール−4−カルボキシラート(工程Aより)から、中間体(i−7)工程Bに概説された方法に従って調製した。
1H NMR(500MHz,CDCl3)δ:9.26(br s,1H),3.81(q,J=7.3及び5.9,1H),2.75(m,2H),2.68(s,3H),2.24(m,1H),2.18−2.01(m,2H),1.82(m,1H).
2−[(Tert−ブトキシカルボニル)アミノ]−4,5,6,7−テトラヒドロ−1,3−ベンゾチアゾール−4−カルボン酸(i−11)
1H NMR(500MHz,DMSO−d6)δ:9.28(br s,2H),4.11(q,J=7.3,2H),3.71(t,J=5.0,1H),2.57−2.39(m,2H),1.90(m,2H),1.78(m,1H),1.59(m,1H),1.17(t,J=7.3,3H).
エチル2−アミノ−4,5,6,7−テトラヒドロ−1,3−ベンゾチアゾール−4−カルボキシラート(工程Aより)から、中間体8(i−8)工程B及びCに概説された方法に従って調製した。
1H NMR(500MHz,CDCl3)δ:3.70(t,J=5.2,1H),2.74(m,1H),2.64(m,1H),2.25(m,1H),2.10−1.94(m,2H),1.87(m,1H),1.55(s,9H).
インダン−1−カルボン酸(i−12)
Tert−ブチル(2S,5R)−2−(4−アミノベンジル)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−1−カルボキシラート(i−13a);
Tert−ブチル(2R,5R)−2−(4−アミノベンジル)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−1−カルボキシラート(i−13b)
LC/MS354.3(M+23).
LC/MS356.3(M+23).
LC/MS475.4(M+23).
LC/MS435.4(M+23).
エタノール(20mL)中の工程Dよりの、上記(シス)tert−ブチル(2R,5S)−2−[(R)−ヒドロキシ(フェニル)メチル]−5−(4−ニトロベンジル)ピロリジン−1−カルボキシラート(1.51g、3.66mmol)の溶液に、10% Pd/C 0.15gを添加し、得られた懸濁液を水素バルーン下、室温で5時間攪拌した。セライトを通して濾過し、溶媒を除去して、標題化合物 1.40g(100%)を白色泡沫として得て、これをさらに精製することなく使用した。
LC/MS405.3(M+23).
エタノール(40mL)中の工程Dよりの(トランス)tert−ブチル(2R,5R)−2−[(R)−ヒドロキシ(フェニル)メチル]−5−(4−ニトロベンジル)ピロリジン−1−カルボキシラート(3.90g、9.46mmol)の溶液に、10% Pd/C 0.4gを添加し、得られた懸濁液を、水素バルーン下、室温で6時間攪拌した。固体を、セライトを通して濾去した。溶媒の除去後、Biotage Horizon(登録商標)システム(シリカゲル、0〜30%酢酸エチル(ヘキサン中)の勾配、次に30%酢酸エチル(ヘキサン中))でのフラッシュクロマトグラフィーにより、標題化合物 2.30g(64%)を白色泡沫として得た。
LC/MS405.3(M+23).
(2S)−1−(1,3−ベンゾチアゾール−2−イル)ピロリジン−2−カルボン酸(i−14):
1H NMR(DMSO−d6):δ7.78(d,J=8.0Hz,1H),7.45(d,J=8.0Hz,1H),7.28(t,J=7.8Hz,1H),7.08(t,J=7.8Hz,1H),4.48(d,J=7.3Hz,1H),3.52−3.61(m,2H),2.37(m,1H),2.01−2.11(m,3H).LC/MS249.3(M+1)
[(6S)−4−オキソ−4,6,7,8−テトラヒドロピロロ[1,2−]ピリミジン−6−カルボン酸(i−44)の調製
LC/MS195.2(M+1).
1H NMR(DMSO−d6):δ7.89(d,J=6.6Hz,1H),6.24(d,J=6.6Hz,1H),4.92(dd,J=10.0,3.1Hz,1H),3.12−2.99(m,2H),2.52(m,1H),2.11(m,1H).LC/MS181.2(M+1).
(3S)−5−オキソ−1,2,3,5−テトラヒドロインドリジン−3−カルボン酸(i−46)
LC−MS:m/z(ES)194(MH)+.
1H NMR(500MHz,CD3OD):δ7.53(dd,J=8.9,7.1Hz,1H),6.38−6.35(m,2H),5.11(dd,J=9.7,2.7Hz,1H),3.23−3.12(m,2H),2.62−2.53(m,1H),2.35−2.30(m,1H).
LC−MS:m/z(ES)180(MH)+.
2−(3−メチル−1H−1,2,4−トリアゾール−1−イル)プロパン酸(i−56)
1H−NMR(500MHz,CDCl3)δ8.05(s,1H),4.90(q,J=7Hz,1H),2.35(s,3H),1.72(d,J=7Hz,3H),1.40(s,9H).ESI−MSC10H17N3O2の計算値:精密質量:211.13;実測値156.05(−tBu).
ESI−MSC6H9N3O2の計算値:精密質量:155.07;実測値156.05.
2−(2−アミノ−1,3−チアゾール−4−イル)−N−[4−({(5R)−[(R)−ヒドロキシ(フェニル)メチル]ピロリジニル}メチル)フェニル]アセトアミド
m/z(ES)637(MH)+,659(MNa)+.
m/z(ES)423(MH)+.(約5:1混合物)1H NMR(500MHz,CD3OD)δ:7.56(br d,J=8.2Hz,2H),7.44(d,7.8Hz,2H),7.39(t,J=7.6Hz,2H)7.35−7.32(m,0.8H)7.32−7.29(m,0.2H副異性体),7.26(d,J=8.0Hz,1.7H),7.14(d,J=8.1Hz,0.3H副異性体)6.67及び6.66(br s,0.2/0.8H,全1H).4.72(d,J=8.5Hz,1H),3.80−3.70(m,4H)3.14(dd,J=6.1,13.8Hz,1H),2.95(dd,J=9.1,13.8Hz,1H),2.08−2.00(m,1H),1.86−1.74(m,3H).
2−(2−アミノ−1,3−チアゾール−4−イル)−N−[4−({(2S,5R)−[(R)−ヒドロキシ(フェニル)メチル]ピロリジニル}メチル)フェニル]アセトアミド
m/z(ES)637(MH)+,659(MNa)+.
m/z(ES)423(MH)+.1H NMR(500MHz,CD3OD)δ:7.55(br d,J=8.2Hz,2H),7.44(d,7.8Hz,2H),7.39(t,J=7.6Hz,2H)7.35−7.33(m,1H),7.25(d,J=8.0Hz,2H),6.65(br s,1H).4.72(d,J=8.5Hz,1H),3.80−3.72(m,4H)3.14(dd,J=6.1,13.8Hz,1H),2.96(dd,J=9.1,13.8Hz,1H),2.07−2.00(m,1H),1.85−1.73(m,3H).
2−アミノ−N−[4−{((2S,5R)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−2−イル)メチル}フェニル]−5,6−ジヒドロ−4H−シクロペンタ[α][1,3]チアゾール−4−カルボキサミド
チアゾール−4−イル}カルボニル)アミノ]ベンジル)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−1−カルボキシラート
チアゾール−4−イル}カルボニル)アミノ]ベンジル)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−1−カルボキシラート(工程Aより、2番目に溶出する異性体)126mg(0.19mmol)の溶液に、トリフルオロ酢酸(3.0mL、38mmol)を添加し、得られた混合物を室温で4時間攪拌した。混合物を蒸発させ、SCXカートリッジを通し、2M NH3(メタノール中)で溶出して、塩基を除去した。生成物を、PREP−TLC 2x[20x20cmx1000ミクロン]溶出液:15% MeOH(DCM中)+1%NH4OH、により精製し、生成物を凍結乾燥して、標題化合物(65mg、75%)を白色の飛散性固体として得た。
m/z(ES)449(MH)+.1H NMR(500MHz,DMSO−d6)δ:10.00(s,1H),7.51(d,J=8.2,2H),7.30(m,4H),7.21(t,J=6.9,1H),7.12(d,J=8.2,2H),6.86(s,1H),4.23(d,J=7.3,1H),3.78(m,1H),3.21(m,1H),3.10(m,1H)2.78(m,1H),2.66(m,2H),2.57(m,2H),2.49(m,1H),1.59(m,1H),1.40(m,1H),1.39(m,2H).
m/z
(ES) 449
(MH) +.
上記記載のものと同様の方法を用いて、化合物4〜10を適切な出発物質から調製した。
N−(4−(((2S,5R)−5−((R)−ヒドロキシ(フェニル)メチル)ピロリジン−2−イル)メチル)フェニル)−2−(3−メチル−1H−1,2,4−トリアゾール−1−イル)プロパンアミド
1H−NMR(500MHz,CD3OD)δ8.51(s,1H),7.49(d,J=13Hz,2H)7.35−7.29(m,4H),7.26−7.20(m,4H),5.20(q,J=7.5Hz,1H),4.20(d,J=7.5Hz,1H),3.27−3.22(m,2H),2.80−2.72(m,2H),2.34(s,3H),1.82(d,J=7.5Hz,3H),1.79−173(m,1H),1.52−1.48(m,3H).ESI−MSC24H29N5O2の計算値:精密質量:419.23,実測値420.35.
(3S)−N−[4−({(2S,5R)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−2−イル}メチル)フェニル]−5−オキソ−1,2,3,5−テトラヒドロインドリジン−3−カルボキサミド(化合物12)及び(3R)−N−[4−({(2S,5R)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−2−イル}メチル)フェニル]−5−オキソ−1,2,3,5−テトラヒドロインドリジン−3−カルボキサミド(化合物13)
LC−MS:m/z(ES)544.2(MH)+.
2番目に溶出するジアステレオマーは、異性体1と命名され、無色の固体である(0.650g、75%)。
LC−MS:m/z(ES)544.2(MH)+.
1H−NMR(500MHz,CD3OD)δ7.89(s,1H),7.54(dd,J=8.8,7.2Hz,1H),7.50(d,J=8.2Hz,2H),7.34−7.29(m,4H),7.26−7.23(m,1H),7.20(d,J=8.2Hz,2H),6.38−3.36(m,2H),5.24(dd,J=9.4,2.8Hz,1H),4.20(d,J=7.8Hz,1H),3.35−3.23(m,3H),3.19−3.12(m,1H),2.82−2.71(m,2H),2.60−2.51(m,1H),2.37−2.32(m,1H),1.79−1.72(m,1H),1.52−1.43(m,3H).
LC−MS:m/z(ES)444.0(MH)+.
LC−MS:m/z(ES)444.0(MH)+.
(6S)−N−[4−({(2S,5R)−5−[(R)−ヒドロキシ(フェニル)メチル]ピロリジン−2−イル}メチル)フェニル]−4−オキソ−4,6,7,8−テトラヒドロピロロ[1,2−α]ピリミジン−6−カルボキサミド
1H NMR(CDCl3):δ9.61(s,1H),7.93(d,J=6.6Hz,1H),7.49(d,J=8.4Hz,2H),7.35−7.28(m,5H),7.13(d,J=8.5Hz,2H),6.40(d,J=6.7Hz,1H),5.36(d,J=8.6Hz,1H),4.38(m,1H),4.12−4.04(m,2H),3.46(m,1H),3.15−3.06(m,2H),2.91(dd,J=13.1,9.0Hz,1H),2.55(m,1H),2.38(m,1H),1.71−1.49(m,13H).LC−MS567.4(M+23).
1H NMR(DMSO−d6):δ10.40(s,1H),7.91(d,J=6.7Hz,1H),7.49(d,J=8.3Hz,2H),7.32−7.26(m,4H),7.21(m,1H),7.15(d,J=8.4Hz,2H),6.23(d,J=6.7Hz,1H),5.11(dd,J=9.6,2.9Hz,1H),5.10(br,1H),4.21(d,J=7.1Hz,1H),3.20−3.00(m,4H),2.66−2.51(m,3H),2.16(m,1H),1.57(m,1H),1.38(m,1H),1.29−1.23(m,2H).LC−MS445.3(M+1)
以下のインビトロのアッセイは、選択的β3アゴニスト活性を有する化合物をスクリーニングするのに適している:
機能アッセイ: リガンドに応答するcAMP産生を、バートン(Barton)ら(「Agonist−induced desensitization of D2 dopamine receptors in human Y−79 retinoblastoma cells(ヒトY−79網膜芽腫細胞におけるD2ドーパミン受容体のアゴニスト誘導性脱感作),Mol.Pharmacol.」、1991年、第3229巻、p.650〜658)に従い、以下のように修正して測定する。cAMP産生は、均一時間分解蛍光共鳴エネルギー転移免疫アッセイ(ランス(LANCETM)、パーキン・エルマー(Perkin Elmer))を用いて、製造業者の指示に従って測定する。クローニングされたβ−アドレナリン作動性受容体(β1、β2、又はβ3)で安定にトランスフェクトされたチャイニーズハムスター卵巣(CHO)細胞は、継代の3日後に収集する。細胞の収穫は、無酵素解離培地(Enzyme−free Dissociation Media)(Specialty Media)を用いて行なう。次に細胞をカウントし、ホスホジエステラーゼ阻害剤(IBMX、0.6mM)を含有するアッセイバッファ(5mM HEPES、0.1%BSAを補足したハンクス平衡塩類溶液(Hank’s Balanced salt solution))中に再懸濁する。反応は、6μL中の6,000個の細胞を、アレクサフルオル(Alexa Fluor)標識cAMP抗体(LANCETMキット)6μLと混合することにより開始し、これを次に、化合物(アッセイバッファで2X最終濃度に希釈)12μLを含有するアッセイウェルに添加する。反応は、室温で30分間進行させ、検出バッファ(LANCETMキット)24μLの添加により終了させる。次にアッセイプレートを、室温で1時間インキュベートし、パーキン・エルマー・エンビジョン・リーダー(Perkin Elmer Envision reader)又は同等物により、時間分解蛍光を測定する。蛍光レベルを、cAMPの標準曲線と比較することにより、未知のcAMPレベルを測定する。
β3−ARアゴニスト、抗ムスカリン剤、及び任意の選択的M2アンタゴニストの同時投与の効果は、以下の実施例において例示される。
材料及び方法
以下の材料及び方法を、実施例1〜3に使用した。雄成体スプラーグ・ドーリー(Sprague−Dawley)ラットを使用した。CO2ガスを用いて安楽死させた後、全膀胱を取出した。三角部外側部分の排尿筋の長軸方向の細片(約6mmx3mm)を用意した。各細片を、酸素化された(95%O2+5%CO2)クレブス(Krebs)溶液を含有する、温めた(37℃)臓器浴(25mL)中に置いた。細片は、一方の端を臓器浴につなげ、他端を等尺性の変換器(ADインスツルメンツ(Instruments))に、10mNの静止張力下で連結した。標本の応答は、多チャンネルデータ収録システム(PowerLab、AD Instruments)により、10Hzのサンプリング率で記録し、分析ソフトウェア(Chart、AD Instruments)で測定した。少なくとも60分間の平衡化時間の後、各組織細片を、60Hz;持続時間、0.3ms;3秒間;90Vでの電気的フィールド刺激(EFS)で誘発し、収縮を誘導した。EFSにより安定な収縮が得られれば、化合物溶液(25μL)を、次第に増加する様式で臓器浴中に適用した。各化合物による処理の15分後、EFSを適用した。
アイソボログラム分析を使用して、併用療法の相乗効果を評価した。アイソボログラム分析は、2つの異なる薬剤の相互作用について、独立した統計解析を用いて視覚的評価を提供する。統計解析は、各化合物の単一処理及び同じ効果を得るための固定比率組合せからの、いくつかの効力指数の計算から遂行される。アイソボログラム分析は、「JPET」、2001年、第298巻、p.865〜872(これは、その記載全体が本明細書に援用される)にさらに詳細に記載されている。
β 3 −ARアゴニストCL316243の、トルテロジン、オキシブチニン、及びダリフェナシンから選択される抗ムスカリン剤との併用療法
個別に投与した場合、CL316243の、トルテロジン、オキシブチニン、及びダリフェナシンの各々は、EFS−誘導性の単離排尿筋収縮を阻害した。表5は、25%阻害を誘導した各化合物の濃度を示す。これらの値を、以下のアイソボログラム分析に使用した。
トルテロジン又はダリフェナシンとの併用における、β 3 −ARアゴニスト、化合物12
この実施例では、異なるβ3−ARアゴニストを使用して、β3−ARアゴニストと抗ムスカリン剤との併用療法の相乗効果を調べた。
併用療法の相乗効果に対する選択的M 2 アンタゴニストの影響
この実施例では、β3−ARアゴニストと、40より大きいM2/M3比をもつ抗ムスカリン剤との併用療法に対する、選択的M2アンタゴニストの影響を調べる。
相乗効果に対する組合せ比の影響
材料及び方法
動物:雌のSDラット(体重200〜250g)(合計7群)。
麻酔:ウレタン(1.0g/kg、ip)。
パラメータ:拡張誘導性の律動的膀胱収縮の振幅
化合物:オキシブチニン(OXY)、CL316243(CL)。
分析:ID20値(振幅を20%まで低減する用量)を用いたアイソボログラム。
ビヒクル(生理食塩水);
OXY、0.01、0.03、0.1mg/kg、iv;
CL、0.003、0.01、0.03mg/kg、iv。
β3−ARアゴニストと抗ムスカリン剤とを含んでなる組合せ組成物
β3−ARアゴニストと抗ムスカリン剤とを含んでなる、例示的な組合せ組成物を、表8に示す。
CR抗ムスカリン剤及びIR β3−ARアゴニストを含んでなる組合せ組成物
制御放出(CR)部分に抗ムスカリン剤を、そして即時放出(CR)部分にβ3−ARアゴニストを含んでなる例示的な組合せ組成物を、表9に示す。
アカゲザルにおける膀胱容量に対する併用療法の効果
材料及び方法
体重5.3〜6.2kg(4〜7歳齢)の成体雌のアカゲザル(Macaca mulatta)を使用した。被験者は、二匹一組又は単独のいずれかで、12時間明/12時間暗のサイクル(7:00AMに点灯)において収容した。彼女らの食餌は、2050テクラド(Teklad)(ハーラン・ラボラトリーズ(Harlan Laboratories)、インディアナ州、インディアナポリス)及び新鮮な果物又は野菜から構成された。水は自由に摂取させた。動物は全て、獣医技術者及び管理人により、健康障害の徴候について毎日観察した。被験者は、>13日の休止期間をとって反復使用された。サルは、テラゾール(Telazol)(3〜5mg/kg)又はケタミン(10〜20mg/kg)のいずれかの筋肉内注射と、その後のシリンジポンプ(552222、ハーバード・アパレイタス(Harvard Apparatus)、マサチューセッツ州、ホリストン)を用いたケタミン(0.2〜0.8mg/kg/分)の静脈内定速輸液によって麻酔した。動物を仰臥位に置き、トリプルルーメンバルーン経尿道カテーテル(7.4Fr、クック・メディカル(Cook Medical、インディアナ州、ブルーミントン)を膀胱に挿入し、バルーンを水 1mLで膨らませて、カテーテルの先端を膀胱の基底部に固定した。カテーテルは、膀胱を充填するための輸液ポンプ(ジェミニ(Gemini)PC−2TX、アラリス・メディカル・システムズ(ALARIS Medical Systems)、カリフォルニア州、サンディエゴ)、及び膀胱内圧をモニタリングするための圧力変換器に連結した。膀胱内圧は、多チャンネルデータ収録システム(Power lab、AD Instruments、バイオパック・システムズ(Biopac systems)、コロラド州、コロラドスプリングス)を用いて、20Hzのサンプリング率で連続的に記録した。超音波診断(Logiq e vet、GEメディカル・システムズ(Medical Systems)、ウィスコンシン州、ウォーキショー、図1A)により膀胱が空であることを確認した後、生理食塩水を15mL/分で膀胱内に注入した。排尿反射の圧力指標に急峻な上昇が観察されたとき、膀胱内注入を停止し、膀胱を60mlシリンジにより手作業で空にした。2回のベースラインシストメトリーの読み取りの後、薬剤を、濃度の上昇するパラダイムを用いて、各投与の10分後にシストメトリーを実施することにより、3回静脈内投与した。膀胱容量は、各シストメトリーについて測定し、ベースライン容量からの%変化を計算した。本明細書で用いるとき、「ベースライン容量」又は「ベースライン」は、2回の投与前測定値の平均膀胱容量を意味する。
Claims (18)
- 過活動膀胱を治療するための医薬組成物またはキットであって、
β3−ARアゴニスト及び
抗ムスカリン剤を含み、
さらに、選択的M2アンタゴニストを含んでもよく;
ここで、前記β3−ARアゴニストが:
からなる群より選択され、
前記抗ムスカリン剤が、40未満のM 2 /M 3 比を有する医薬組成物またはキット。 - 前記抗ムスカリン剤が、20未満のM2/M3比を有する、請求項1に記載の医薬組成物またはキット。
- 前記抗ムスカリン剤が:トルテロジン、フェソテロジン、オキシブチニン、ソリフェナシン、プロピベリン、トロスピウム、イミダフェナシン、及びTD6301からなる群より選択される、請求項1に記載の医薬組成物またはキット。
- 前記抗ムスカリン剤が、トルテロジン又はオキシブチニンである、請求項3に記載の医薬組成物またはキット。
- 前記β3−ARアゴニストが:
からなる群より選択される、請求項1に記載の医薬組成物またはキット。 - 前記β3−ARアゴニスト及び前記抗ムスカリン剤が、300:1ないし1:10の重量比で前記患者に投与される、請求項5に記載の医薬組成物またはキット。
- 前記抗ムスカリン剤が、トルテロジンであり、かつここで、前記β3−ARアゴニスト及びトルテロジンが、300:1ないし1:1の重量比で前記患者に投与される、請求項5に記載の医薬組成物またはキット。
- 過活動膀胱を治療するための医薬組成物またはキットであって、
β3−ARアゴニスト、
抗ムスカリン剤、及び
選択的M2アンタゴニスト
を含んでなり;
ここで、前記β3−ARアゴニストが:
からなる群より選択される、組成物またはキット。 - 前記抗ムスカリン剤が、40より大きいM2/M3比を有する、請求項8に記載の医薬組成物またはキット。
- 前記抗ムスカリン剤が、ダリフェナシンであり、かつ前記選択的M2アンタゴニストが、メトクトラミンである、請求項9に記載の医薬組成物またはキット。
- 過活動膀胱を治療する医薬組成物またはキットであって、
CL316243及び
オキシブチニン
を含んでなり;
ここで、CL316243及びオキシブチニンが、1:1又は1:10の重量比で前記患者に投与される、該医薬組成物またはキット。 - 前記β3−ARアゴニスト、前記抗ムスカリン剤、及び前記選択的M2アンタゴニストが、同時に、別々に、又は連続的に投与される、請求項1または8に記載の医薬組成物またはキット。
- 前記β3−ARアゴニスト、前記抗ムスカリン剤、及び前記選択的M2アンタゴニストが、経口的に投与される、請求項1または8に記載の医薬組成物またはキット。
- 医薬組成物であって:
β3−ARアゴニスト及び
抗ムスカリン剤
を含んでなり;
ここで、前記β3−ARアゴニストが:
からなる群より選択され、
かつ、前記抗ムスカリン剤が、40未満のM 2 /M 3 比を有する該組成物。 - 前記抗ムスカリン剤が、トルテロジン、オキシブチニン、フェソテロジン、ソリフェナシン、プロピベリン、及びトロスピウムからなる群より選択される、請求項14に記載の医薬組成物。
- 医薬組成物であって:
β3−ARアゴニスト、
抗ムスカリン剤、及び
選択的M2アンタゴニストを、
含んでなり;
ここで、前記β3−ARアゴニストが:
からなる群より選択され、
ここで、前記抗ムスカリン剤が、ダリフェナシンであり、かつ
前記選択的M2アンタゴニストが、メトクトラミンである、該医薬組成物。 - 前記組成物が、経口投与用の錠剤又はカプセルである、請求項14または16に記載の医薬組成物。
- 前記組成物が、抗ムスカリン剤の制御放出を提供する、請求項14または16に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24938609P | 2009-10-07 | 2009-10-07 | |
US61/249,386 | 2009-10-07 | ||
PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013507363A JP2013507363A (ja) | 2013-03-04 |
JP5738871B2 true JP5738871B2 (ja) | 2015-06-24 |
Family
ID=43857059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012533204A Active JP5738871B2 (ja) | 2009-10-07 | 2010-09-27 | β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20120202819A1 (ja) |
EP (1) | EP2485595A4 (ja) |
JP (1) | JP5738871B2 (ja) |
KR (1) | KR20120093859A (ja) |
CN (1) | CN102638987A (ja) |
AU (1) | AU2010303811B2 (ja) |
BR (1) | BR112012007829A2 (ja) |
CA (1) | CA2774992A1 (ja) |
IL (1) | IL218756A0 (ja) |
IN (1) | IN2012DN02782A (ja) |
MX (1) | MX2012004134A (ja) |
NZ (1) | NZ599233A (ja) |
RU (1) | RU2012118668A (ja) |
WO (1) | WO2011043942A1 (ja) |
ZA (1) | ZA201202520B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
US8940763B2 (en) * | 2011-05-10 | 2015-01-27 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
JP6063948B2 (ja) | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ベータ3アゴニストおよび中間体を製造するプロセス |
ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
TW201338772A (zh) * | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
WO2014150639A1 (en) * | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Process for preparing beta 3 agonists and intermediates |
DK3024474T3 (da) * | 2013-07-23 | 2022-03-28 | Serenity Pharmaceuticals Llc | Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist |
KR20170097045A (ko) | 2014-11-20 | 2017-08-25 | 알레간 인코포레이티드 | 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물 |
KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
EP3324966A4 (en) * | 2015-07-20 | 2019-04-10 | Chase Pharmaceuticals Corporation | MUSCARINIC COMBINATION OF A SELECTIVE M2 RECEPTOR ANTAGONIST AND A PERIPHERAL NON-SELECTIVE ANTAGONIST FOR THE TREATMENT OF HYPOCHOLINERGIC DISORDERS |
IL310527A (en) | 2015-10-23 | 2024-03-01 | B3Ar Therapeutics Inc | Zwitterion solvegron and its uses |
WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
US11376253B2 (en) * | 2017-12-21 | 2022-07-05 | Kyorin Pharmaceutical Co., Ltd. | Agent for treating nocturnal pollakiuria |
CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
WO2006042679A1 (de) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
EP2141992A1 (en) * | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Application Discontinuation
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en active Application Filing
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2485595A1 (en) | 2012-08-15 |
MX2012004134A (es) | 2012-05-08 |
KR20120093859A (ko) | 2012-08-23 |
ZA201202520B (en) | 2012-12-27 |
WO2011043942A1 (en) | 2011-04-14 |
RU2012118668A (ru) | 2013-11-20 |
JP2013507363A (ja) | 2013-03-04 |
BR112012007829A2 (pt) | 2015-09-22 |
AU2010303811A1 (en) | 2012-04-19 |
IL218756A0 (en) | 2012-06-28 |
AU2010303811B2 (en) | 2013-01-24 |
US20120202819A1 (en) | 2012-08-09 |
IN2012DN02782A (ja) | 2015-09-18 |
EP2485595A4 (en) | 2014-03-12 |
CA2774992A1 (en) | 2011-04-14 |
NZ599233A (en) | 2013-04-26 |
CN102638987A (zh) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5738871B2 (ja) | β3アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 | |
JP5432846B2 (ja) | β3アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン | |
ES2413504T3 (es) | Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos | |
JP5812500B2 (ja) | 新規なβ3アドレナリン作動性受容体アゴニスト | |
EP2427194B1 (en) | Pyrrolidine-derived beta 3 adrenergic receptor agonists | |
MX2012005258A (es) | El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad. | |
JP2014505688A (ja) | オキサジン誘導体および神経障害の処置におけるその使用 | |
WO2010008864A2 (en) | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors | |
EP2310392A2 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
JP2009512676A (ja) | ムスカリン性受容体アンタゴニストの医薬組成物 | |
Garsi et al. | In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways | |
EP1937264A2 (en) | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | |
CA3233408A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
US20230147458A1 (en) | Imidazopyridazine il-17 inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150331 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150422 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5738871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |